Zivo Bioscience Inc 's ROA from the third quarter of 2025 to the third quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Zivo Bioscience Inc 's ROA in the third quarter of 2025?
Zivo Bioscience Inc recorded a cumulative net loss of $-8 million during 12 months ending in the third quarter of 2025, resulting in a negative return on assets (ROA) of -206.62%.

However, within the Healthcare sector 953 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2025 quarter, so far to 4778, from total ROA ranking in the second quarter of 2025 at 4860.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter
Y / Y Total Assets Change	12.88 %	22.19 %	63.07 %	2389.4 %	-76.42 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-8	-10	-16	-13	-14
Return On Assets (TTM)	-206.62 %	-237.63 %	-402.01 %	-340.56 %	-2241.52 %
ZIVO's Total Ranking	# 4778	# 4860	# 4957	# 5712	# 5106
Total Assets (TTM) in million	1	1	1	14	0
Seq. Total Assets Change	-20.46 %	-47.17 %	-90.38 %	2691.06 %	-13.89 %
Seq. Net Income Change	-	-	-	-	-

ZIVO's 5 Years Annual ROA >> Back to ZIVO Management Effectiveness >> Compare ZIVO ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 149
Sector	# 954
Overall	# 4718

Return On Assets Statistics
High	Average	Low
285.55 %	-1761.91 %	-7026 %
(Sep 30 2014)		(Dec 31 2019)

News about Zivo Bioscience Inc Return on Assets ROA

ZIVO Bioscience Secures Breakthrough in Coccidiosis Treatment for Poultry with Promising Study Resu...

ZIVO Bioscience Achieves Promising Results in Coccidiosis Treatment for Broiler Chickens In an era where sustainable and responsible farming practices are paramount, ZIVO Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech and agtech research and development company, has announced positive outcomes from its recently conducted 42-day confirmatory study on a novel coccidiosis treatment for broiler chickens. Coccidiosis, a significant parasitic disease affecting poultry, is known to cause substantial economic losses in the poultry industry by impacting the growth and overall health of birds. This study was conducted in collaboration with a major global animal health company and was designed to replicate real-world poultry production environments. A Collaborative Endeavor in Animal HealthZIVO, renowned for its commitment to developing therapeutic, medicinal, and nutritional products derived from proprietary algal cultures, launched this study to validate the efficacy of its non-antibiotic, immune-modulating treatment for coccidiosis. The collaboration with a major global player in the animal health industry enhances the credibility of this research and underscores the growing interest in innovative, sustainable alternatives to traditional animal healthcare products.

Financial Statements
Zivo Bioscience Inc 's Assets	$ 1 million	ZIVO's Balance sheet
Zivo Bioscience Inc 's Income	$ -1 million	Quarterly ZIVO's Income Statement
ZIVO's Income by Division		See ZIVO's Income by Division

Annual Return On Assets	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020
Y / Y Total Assets Change	2389.4 %	-71.26 %	-78.42 %	5146.71 %	-63.61 %
Total Assets in million	14	1	2	9	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-13	-8	-9	-9	-9
Annual Return On Assets	-96.76 %	-1399.55 %	-452.24 %	-102.24 %	-5330.29 %

ZIVO's 5 Years Annual ROA >> Back to ZIVO Management Effectiveness >> Compare ZIVO ROA to its Competitors

More Return On Assets Ratios
ZIVO's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ZIVO's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ZIVO's Competitors
Subscribers only: Roa for Zivo Bioscience Inc 's Suppliers
Subscribers only: Return On Assets for ZIVO's Customers

You may also want to know
ZIVO's Roi	ZIVO's Inventory Turnover Ratio	ZIVO's Growth Rates	ZIVO's Dividend Comparisons
	ZIVO's Profitability Ratios	ZIVO's Asset Turnover Ratio	ZIVO's Dividend Growth
ZIVO's Roe	ZIVO's Valuation Ratios	ZIVO's Financial Strength Ratios	ZIVO's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2025, within Healthcare Sector

ROA

Date modified: 2026-09-08T15:11:35+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.